Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021

information fournie par Boursorama CP •09/11/2021 à 14:00

Data support BT-001’s unique dual mode of action

Strasbourg, France, and Lund, Sweden, November 9, 2021, 2:00 pm CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announce preclinical data supporting the mode of action of BT-001, their novel dual mechanism-of-action oncolytic Vaccinia virus. The data demonstrate high intratumoral expression of an immune checkpoint-inhibiting antibody and robust anti-tumoral activity in several tumor models.

.../...